American Capital Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$623K Buy
519
+10
+2% +$10.2K 0.23% 68
2026
Q1
$468K Buy
509
+9
+2% +$9.12K 0.19% 74
2025
Q4
$537K Buy
500
+6
+1% +$5.74K 0.23% 73
2025
Q3
$377K Sell
494
-5
-1% -$3.72K 0.17% 81
2025
Q2
$389K Buy
499
+9
+2% +$6.99K 0.19% 77
2025
Q1
$405K Buy
490
+17
+4% +$14.1K 0.22% 75
2024
Q4
$365K Buy
473
+3
+0.6% +$2.48K 0.2% 81
2024
Q3
$416K Sell
470
-7
-1% -$6.29K 0.24% 71
2024
Q2
$278K Buy
477
+307
+181% +$246K 0.2% 74
2024
Q1
$58.4K Sell
170
-307
-64% -$218K 0.05% 135
2023
Q4
$278K Buy
+477
New +$278K 0.2% 74

Other funds holding LLY

American Capital Advisory's LLY Position: Q2 2026 in Review

American Capital Advisory increased its Eli Lilly (LLY) stake by 2% in Q2 2026, buying an estimated $10.2K and bringing the position to 519 shares worth $623K. The position accounts for 0.23% of the portfolio, ranked #68.

American Capital Advisory first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • American Capital Advisory held 519 shares of Eli Lilly worth $623K as of Q2 2026.
  • American Capital Advisory bought 10 Eli Lilly shares in Q2 2026, an estimated $10.2K.
  • Eli Lilly made up 0.23% of American Capital Advisory's portfolio in Q2 2026, its #68 holding.
  • American Capital Advisory first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.